{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:54:12Z","timestamp":1785884052706,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011676","name":"Elekta AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cct.2026.108381","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:36:42Z","timestamp":1781739402000},"page":"108381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial"],"prefix":"10.1016","volume":"167","author":[{"given":"Harroun","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia S.W.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooya","family":"Alborz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodor","family":"Stanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui Amy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"De Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrick","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweet Ping","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Radhakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Bahij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Intven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kirichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruz","family":"Mesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Augilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cct.2026.108381_bb0005","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1634\/theoncologist.2012-0121","article-title":"The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus","volume":"17","author":"Adam","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0010","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1748-717X-7-126","article-title":"Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review","volume":"7","author":"Almaghrabi","year":"2012","journal-title":"Radiat. Oncol."},{"issue":"10","key":"10.1016\/j.cct.2026.108381_bb0015","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2026.108381_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101760","article-title":"Epidemiology of liver metastases","volume":"67","author":"Horn","year":"2020","journal-title":"Cancer Epidemiol."},{"issue":"4","key":"10.1016\/j.cct.2026.108381_bb0025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.rpor.2020.04.021","article-title":"Stereotactic body radiation therapy for liver metastases: clinical outcomes and literature review","volume":"25","author":"De La Pe\u00f1a","year":"2020","journal-title":"Rep. Pract. Oncol. Radiother."},{"issue":"4","key":"10.1016\/j.cct.2026.108381_bb0030","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.semradonc.2018.06.009","article-title":"A contemporary update on the role of stereotactic body radiation therapy (SBRT) for liver metastases in the evolving landscape of oligometastatic disease management","volume":"28","author":"Robin","year":"2018","journal-title":"Semin. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.cct.2026.108381_bb0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijrobp.2017.04.010","article-title":"Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases","volume":"99","author":"McPartlin","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.cct.2026.108381_bb0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.radonc.2018.06.035","article-title":"Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review","volume":"129","author":"Petrelli","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.cct.2026.108381_bb0045","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2019.08.018","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: dose and site of metastases matter","volume":"142","author":"Thompson","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.cct.2026.108381_bb0050","first-page":"45","article-title":"High versus low dose stereotactic body radiation therapy for hepatic metastases","volume":"20","author":"Kok","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic body radiotherapy (SBRT) for liver metastasis \u2013 clinical outcomes from the international multi-institutional RSSearch\u00ae patient registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","article-title":"Local control after stereotactic body radiation therapy for liver tumors","volume":"110","author":"Ohri","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1245\/s10434-015-4579-z","article-title":"A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases","volume":"23","author":"Meyer","year":"2016","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.cct.2026.108381_bb0070","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ijrobp.2020.12.012","article-title":"Long-term results of a phase 1 dose-escalation trial and subsequent institutional experience of single-fraction stereotactic ablative radiation therapy for liver metastases","volume":"109","author":"Folkert","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.cct.2026.108381_bb0075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/cancers14030716","article-title":"MRI-guided online adaptive stereotactic body radiation therapy of liver and pancreas tumors on an MR-Linac system","volume":"14","author":"Stanescu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cct.2026.108381_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.920443","article-title":"Improving the clinical workflow of a MR-Linac by dosimetric evaluation of synthetic CT","volume":"12","author":"Tang","year":"2022","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.cct.2026.108381_bb0085","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ad6745","article-title":"Development and validation of an MR-driven dose-of-the-day procedure for online adaptive radiotherapy in upper gastrointestinal cancer patients","volume":"69","author":"Semeniuk","year":"2024","journal-title":"Phys. Med. Biol."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0090","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13014-018-1185-9","article-title":"Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up","volume":"13","author":"Scorsetti","year":"2018","journal-title":"Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.cct.2026.108381_bb0095","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.cct.2026.108381_bb0100","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2021.01.004","article-title":"Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer","volume":"110","author":"Zelefsky","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1079","key":"10.1016\/j.cct.2026.108381_bb0105","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170400","article-title":"Optimization of radiotherapy fractionation schedules based on radiobiological functions","volume":"90","author":"Pizarro","year":"2017","journal-title":"Br. J. Radiol."},{"issue":"5","key":"10.1016\/j.cct.2026.108381_bb0110","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clon.2022.02.009","article-title":"How low can you go? The radiobiology of hypofractionation","volume":"34","author":"Brand","year":"2022","journal-title":"Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cct.2026.108381_bb0115","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ijrobp.2012.11.003","article-title":"Dose escalation, not \u201cnew biology,\u201d can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer","volume":"85","author":"Brown","year":"2013","journal-title":"Int. J. Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.cct.2026.108381_bb0120","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.prro.2011.10.004","article-title":"Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control","volume":"2","author":"Mehta","year":"2012","journal-title":"Pract. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"Van Leeuwen","year":"2018","journal-title":"Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.cct.2026.108381_bb0130","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.ijrobp.2018.06.250","article-title":"Estimation of the alpha-beta ratio for chemoradiation of locally advanced pancreatic cancer","volume":"102","author":"Prior","year":"2018","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.cct.2026.108381_bb0135","first-page":"1","article-title":"What would be the most appropriate \u03b1 \/ \u03b2 ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer","volume":"2013","author":"Chi","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.cct.2026.108381_bb0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.radonc.2019.07.008","article-title":"Estimation of the \u03b1\/\u03b2 ratio of non-small cell lung cancer treated with stereotactic body radiotherapy","volume":"142","author":"Klement","year":"2020","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.cct.2026.108381_bb0145","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.radonc.2017.03.014","article-title":"Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5362-5","article-title":"The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases","volume":"19","author":"Klement","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.cct.2026.108381_bb0155","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cct.2026.108381_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109769","article-title":"The impact of local control on widespread progression and survival in oligometastasis-directed SBRT: results from a large international database","volume":"186","author":"Cao","year":"2023","journal-title":"Radiother. Oncol."},{"issue":"9","key":"10.1016\/j.cct.2026.108381_bb0165","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","article-title":"Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?","volume":"55","author":"Stewart","year":"2018","journal-title":"Curr. Probl. Surg."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0170","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1200\/JCO.2001.19.1.164","article-title":"Stereotactic single-dose radiation therapy of liver tumors: results of a phase I\/II trial","volume":"19","author":"Herfarth","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cct.2026.108381_bb0175","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","author":"Hoyer","year":"2006","journal-title":"Acta Oncol."},{"issue":"7","key":"10.1016\/j.cct.2026.108381_bb0180","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study","volume":"45","author":"M\u00e9ndez Romero","year":"2006","journal-title":"Acta Oncol."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.cct.2026.108381_bb0190","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","article-title":"Phase I study of individualized stereotactic body radiotherapy of liver metastases","volume":"27","author":"Lee","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cct.2026.108381_bb0195","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.prro.2017.03.004","article-title":"Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy","volume":"7","author":"Barry","year":"2017","journal-title":"Pract. Radiat. Oncol."},{"issue":"8","key":"10.1016\/j.cct.2026.108381_bb0200","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3346\/jkms.2015.30.8.1055","article-title":"Low hepatic toxicity in primary and metastatic liver cancers after stereotactic ablative radiotherapy using 3 fractions","volume":"30","author":"Bae","year":"2015","journal-title":"J. Korean Med. Sci."},{"issue":"4","key":"10.1016\/j.cct.2026.108381_bb0205","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ijrobp.2018.04.011","article-title":"Baseline albumin-bilirubin (ALBI) score in western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT)","volume":"101","author":"Murray","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.cct.2026.108381_bb0210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease \u2013 influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2018.12.049","article-title":"Predictive factors for response and survival in a cohort of oligometastatic patients treated with stereotactic body radiation therapy","volume":"104","author":"Franceschini","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.cct.2026.108381_bb0220","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.cct.2026.108381_bb0225","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijrobp.2012.12.021","article-title":"Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial","volume":"86","author":"Scorsetti","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.cct.2026.108381_bb0230","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.01.002","article-title":"A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases","volume":"62","author":"Schefter","year":"2005","journal-title":"Int. J. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0235","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/ol.2017.6167","article-title":"Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer","volume":"14","author":"Doi","year":"2017","journal-title":"Oncol. Lett."},{"issue":"11","key":"10.1016\/j.cct.2026.108381_bb0240","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1089\/ars.2009.2692","article-title":"Adaptation to oxidative stress, chemoresistance, and cell survival","volume":"11","author":"Landriscina","year":"2009","journal-title":"Antioxid. Redox Signal."},{"issue":"1","key":"10.1016\/j.cct.2026.108381_bb0245","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1634\/theoncologist.2014-0273","article-title":"Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon","volume":"20","author":"Fink","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.cct.2026.108381_bb0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2021.12.018","article-title":"An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer","volume":"167","author":"Sheikh","year":"2022","journal-title":"Radiother. Oncol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426001679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426001679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:39:10Z","timestamp":1785883150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714426001679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"alternative-id":["S1551714426001679"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2026.108381","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2026.108381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108381"}}